TERN Terns Pharmaceuticals

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m. GMT.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcast will be archived on Terns’ website for at least 30 days following the event.

About Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML. For more information, please visit: .

Contacts for Terns

Investors

Justin Ng

Media

Jenna Urban

CG Life



EN
14/11/2025

Underlying

TERNTerns Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Terns Pharmaceuticals

 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcar...

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m. GMT. A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcast will be archived o...

4h / 10m 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and...

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today reported fi...

November 10, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and w...

November 4, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Announces Abstract with Positive Clinical Data for TERN-701 in R...

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongo...

November 3, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Tr...

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leuk...

October 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch